MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'carboplatin'. Sat, 03 Sep 2011 02:49:46 +0100 http://www.medworm.com/index.php?rid=4433289&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F02%2F03%2Ffda-awards-1-6m-orphan-drug-grant-for-clinical-phase-ii-development-of-egen-001-for-treatment-of-ovarian-cancer%2F EGEN, Inc. announced that the Food and Drug Administration (FDA) awarded the company a four-year grant of $1.6 million to assist in the phase II clinical development of EGEN-001, the company’s lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer. EGEN, Inc. announced that the Food and Drug Administration (FDA) [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4433289 Thu, 03 Feb 2011 21:52:52 +0100 4433289 http://www.medworm.com/index.php?rid=3802551&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F07%2F29%2Fresearchers-identify-missing-link-underlying-dna-repair-platinum-drug-resistance%2F Researchers have discovered an enzyme crucial to a type of DNA repair that also causes resistance to a class of cancer drugs most commonly used against ovarian cancer. Scientists from The University of Texas MD Anderson Cancer Center and the Life Sciences Institute of Zhejiang University in China report the discovery of the enzyme and [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3802551 Fri, 30 Jul 2010 04:45:58 +0100 3802551 http://www.medworm.com/index.php?rid=3501683&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F04%2F23%2Fparp-inhibitor-olaparib-benefits-women-with-inherited-ovarian-cancer-based-upon-platinum-drug-sensitivity%2F Olaparib (AZD2281), a new type of cancer drug known as a “PARP inhibitor,” produced promising results in patients with platinum-refractory, platinum-resistant, and platinum-sensitive ovarian cancer linked to an inherited BRCA1 or BRCA2 gene mutation. A new type of cancer drug — known as a “PARP inhibitor” — produced promising results in patients with ovarian cancer linked [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3501683 Sat, 24 Apr 2010 00:38:57 +0100 3501683 http://www.medworm.com/index.php?rid=3311889&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F02%2F25%2Fgenentech-announces-positive-results-of-avastin-phase-iii-study-in-women-with-advanced-ovarian-cancer%2F Genentech announces positive results of Avastin Phase III study (GOG 218) in women with advanced ovarian cancer. The study showed that women who continued maintenance use of Avastin alone, after receiving Avastin in combination with chemotherapy, lived longer without the disease worsening compared to those who received chemotherapy alone. This is the first Phase [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3311889 Thu, 25 Feb 2010 18:40:30 +0100 3311889 http://www.medworm.com/index.php?rid=3212566&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F01%2F26%2Ftwo-combination-treatment-regimens-added-to-updated-nccn-guidelines-for-ovarian-cancer%2F The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer. The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Ovarian Cancer to reflect the addition of two preferred combination [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3212566 Wed, 27 Jan 2010 04:44:49 +0100 3212566 http://www.medworm.com/index.php?rid=3139103&cid=t_124521_111_f&fid=36048&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FMyb5g2vobFk%2F A study looking at the effectiveness of the drug figitumumab in treating late-stage lung cancer has been stopped by the manufacturer, Pfizer Inc. Late-stage lung cancer is difficult to treat and researchers are continuously looking for different drug combinations that could help increase the survival rate of the disease. This particular study looked at figitumumab in combination with two other chemotherapy agents, paclitaxel and carboplatin. The researchers were comparing the three-drug combination to paclitaxel plus carboplatin alone. In October 2009, Pfizer stopped patient recruitment into the study. Independent monitors had found disturbing outcomes, serious adverse events including deaths, among patients who had been receiving figitumumab. Although the study’s discontinuation is ... A Hearty Life blogs http://www.medworm.com/rss/comments.php?id=3139103 Mon, 04 Jan 2010 09:01:09 +0100 3139103 http://www.medworm.com/index.php?rid=2984987&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F11%2F11%2Fucla-researchers-significantly-inhibit-growth-of-ovarian-cancer-cell-lines-with-fda-approved-leukemia-drug-dasatinib-sprycel%25c2%25ae%2F The drug dasatinib (Sprycel®), approved for use by the U.S. Food and Drug Administration in patients with specific types of leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, say UCLA researchers in the November 10th issue of the British Journal of Cancer. The drug, when paired with [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2984987 Thu, 12 Nov 2009 00:45:53 +0100 2984987 http://www.medworm.com/index.php?rid=2832371&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F09%2F24%2Fmodified-chemo-regime-increases-survival-in-advanced-ovarian-cancer-patients-but-adds-toxicity%2F Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers reported last week. In a large phase III clinical trial, women who received carboplatin every 3 weeks and a reduced dose of paclitaxel (Taxol®) once a week for 3 weeks [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2832371 Thu, 24 Sep 2009 20:44:57 +0100 2832371 http://www.medworm.com/index.php?rid=2512799&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F06%2F18%2F2009-asco-annual-meeting-highlights-ovarian-cancer-select-general-issues%2F The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, Florida from May 29 through June 2, 2009.  We provide below select highlights from the 2009 ASCO Annual Meeting that relate to ovarian cancer and other general issues. The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2512799 Thu, 18 Jun 2009 22:11:35 +0100 2512799 http://www.medworm.com/index.php?rid=2390260&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F06%2Fpattern-of-genetic-faults-could-predict-whether-an-ovarian-cancer-patient-will-respond-to-common-chemo-drugs%2F “… A pattern of genetic defects in tumours could indicate whether ovarian cancer patients will respond to common chemotherapy drugs before treatment starts, reveals a Cancer Research UK study published in the Proceedings of the National Academy of Sciences … The researchers studied patterns of gene expression that indicate high levels of abnormal chromosomes or [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2390260 Thu, 07 May 2009 01:16:10 +0100 2390260 http://www.medworm.com/index.php?rid=2349512&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F19%2Faddition-of-dasatinib-sprycel-to-standard-chemo-cocktail-may-enhance-effect-in-certain-ovarian-cancers%2F “The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.  ‘We know that a pathway called SRC is involved in cell proliferation in [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2349512 Mon, 20 Apr 2009 06:42:05 +0100 2349512 http://www.medworm.com/index.php?rid=2260416&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F09%2Fmd-anderson-researchers-find-gm-csf-and-rifn-gamma1b-plus-carboplatin-effective-for-the-treatment-of-recurrent-platinum-sensitive-ovarian-cancer%2F Researchers working in the Gynecologic Oncology Department of The University of Texas M.D. Anderson Cancer Center, reported Phase II clinical study results from their evaluation of the use of carboplatin, granulocyte-macrophage colony-stimulating factor (GM-CSF) and recombinant interferon gamma 1b (rIFN-gamma1b) in women with recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. … Researchers working in [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2260416 Mon, 09 Mar 2009 23:35:16 +0100 2260416 http://www.medworm.com/index.php?rid=2235722&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F05%2Fevaluation-of-neoadjuvant-chemotherapy-and-debulking-followed-by-intraperitoneal-chemotherapy-in-women-with-stage-iii-and-iv-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer%2F It is well known that intraperitoneal (IP) chemotherapy prolongs survival in optimally cytoreduced (or debulked) ovarian cancer patients.  For patients who can not be optimally debulked, it is possible to administer neoadjuvant chemotherapy to place that patient in a position to be optimally debulked (i.e., 1 cm or less of residual disease post surgery) , [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2235722 Fri, 06 Mar 2009 00:43:55 +0100 2235722 http://www.medworm.com/index.php?rid=2218537&cid=t_124521_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F02%2F25%2Fsometimes-more-is-less-evaluation-of-experimental-platinum-based-treatment-regimens-in-advanced-stage-ovarian-cancer-a-phase-iii-trial-of-the-gynecologic-cancer-intergroup%2F “… Compared with standard paclitaxel and carboplatin, addition of a third cytotoxic agent [gemcitibine, liposomal doxorubicin or topotecan] provided no benefit in PFS [progression-free survival] or OS [overall survival] after optimal or suboptimal cytoreduction. Dual-stage, multiarm, phase III trials can efficiently evaluate multiple experimental regimens against a single reference arm. The development of new interventions [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2218537 Wed, 25 Feb 2009 23:36:44 +0100 2218537 http://www.medworm.com/index.php?rid=675433&cid=t_124521_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F06%2F13%2Fadvanced-lung-cancer-and-treatment-drug-cisplatin%2F Filed under: Drug, Chemotherapy, Lung Cancer, Clinical Trials, ResearchA report published in the Journal of the National Cancer Institute has stated that cisplatin has better response rates than carboplatin in the treatment of advanced non-small cell lung cancer. The two main types of lung cancer, accounting for over 90 percent of all lung cancers, are non-small cell and small cell cancer. Non-small cell lung cancer (NSCLC) accounts for most of that 90 percent. Advanced NSCLC means that the patient's cancer has spread to other organs or areas of the body. There has been research done to evaluate which drug is better for NSCLC -- cisplatin or carboplatin. Nine clinical trials were analyzed to see what regime is a better treatment option. The study concluded that 30 percent of patients trea... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=675433 Wed, 13 Jun 2007 04:00:00 +0100 675433